/ / /

OUR WORK IN IMMUNO-ONCOLOGY

Cancer Cases Continue to Rise

While global cancer cases continue to rise, the fight is personal – not only for patients and their loved ones but also for those focused on treating cancer and developing new treatments.¹

18 Million

In 2018, it is estimated that approximately 18 million people worldwide were diagnosed and about 9.5 million people died from cancer.²

20 Million

By 2025, new cancer cases worldwide are predicted to exceed 20 million annually.³

Visionary Science: Immuno-Oncology

Today, every member of our team remains committed to smartly and collaboratively accelerating the drug development process and the speed with which we can bring forward new approaches to treat people with cancer.

UNDERSTANDING THE IMMUNE SYSTEM AND CANCER

The Past:

In the 1950s, researchers proposed that the immune system patrols the body to detect and destroy tumor cells. Scientists and researchers had previously focused on cancer cells and treating cancer as a genetic disease.⁴

The Present:

Now the focus is shifting to the microenvironment in which cancer grows, including the immune system – an approach called immuno-oncology.⁴

The Future:

Immuno-Oncology has the potential to transform how physicians treat cancer and how patients benefit.⁴

OUR INSPIRATION

We believe in the work we do and are working with the entire cancer community to help people with cancer and their caregivers better navigate their journeys.

Ultimately, our progress in changing the outcomes of cancer would not be possible without:

... the participation of patients in clinical trials

... the support and involvement of the physicians who believe in the importance of advancing the care for patients through innovative clinical trials

... the patient advocacy community who helps support people with cancer through their journeys

¹ American Cancer Society
² Bray et all, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, Cancer Journal for Clinicians, August 2018;68:394–424,
³ World Cancer Report 2014, IARC
⁴ merck.com > Oncology

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.